Bold Therapeutics Receives FDA Clearance to Add U.S. Sites for Phase 1b / 2a Trial of BOLD-100 in the Treatment of Advanced GI Cancers

VANCOUVER, BC: VANCOUVER, BC, July 7, 2021 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug Application (IND) amendment for BOLD-100-001, allowing for the addition of clinical trial sites in the United States,...

Click to view original post